Beyond HbA1C: Overcoming Challenges in Insulin-Treated Type 2 Diabetes
Dr Daphne Gardner talks about overcoming challenges in insulin-treated type 2 diabetes with the help of continuous glucose monitoring and AI-assisted technology.
Related Links
- Continuous Glucose Monitoring with AI-enabled Predictive Algorithms for Diabetes Care: Expert Views from Hong Kong
- Diabetes and Hajj: Doctor’s Awareness Program
- STRONG-HF Japan Study
- Diabetes and Ramadan: Public Awareness Program
- Ramadan & Diabetes
- International Speaker Program (ISP) From Diabetes to Wellbeing: A Global Dialogue on Holistic Health
- Culturally Sensitive Diabetes Care
- What Causes Falsely High & Low HbA1c Reading?
- Menopause and Diabetes
- EMPORIUM – Full Throttle Against HF: From Detection to Protection
- Every Heartbeat Counts: Take Action & Make an Impact This World Heart Day
- The effectiveness of telemonitoring and integrated personalised diabetes management in people with insulin-treated type 2 diabetes mellitus
- Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)
- Communicating the value of CVD screening in T2DM to patients
- Management of CVD in Patients with Diabetes
- Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients
- Elevating CVD management in APAC to its Zenith- with Cardiac biomarkers
- Uncovering the Cardio-renal Risks of Chinese T2DM patients: Back to the Future with CUHK!
- Management of Diabetes in Japan – Can Patients Play a More Significant Role?
- T2DM Patient Support Program in Hong Kong and the Value of NT-proBNP
- Role of Diagnostics: NT-proBNP in management of Heart Failure
- Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients
- NT-proBNP: Increasing Clinical Confidence in Heart Failure Management
- Heart Failure Prevention in T2DM – Essence of JCS/JDS joint consensus
- CVD Management in T2DM – JCS and JDS Joint Consensus
- APSC hs-TnT Consensus & Future Use of Biomarker in T2DM & COVID-19